Cormorant Asset Management, LP Q1 2021 Filing

Filed May 17, 2021

Portfolio Value

$4.5T

Holdings

119

Report Date

Q1 2021

Filing Type

13F-HR

All Holdings (119 positions)

#StockSharesValue% PortfolioType
101
CLDNEUREIGER BIOPHARMACEUTICALS INC
400,000$3.5B0.08%
102
KADMON HLDGS INC
750,000$2.9B0.07%
103
ALLKGUSDALLAKOS INC
25,000$2.9B0.06%
104
NUVBNUVATION BIO INC
234,445$2.5B0.05%
105
AUTLAUTOLUS THERAPEUTICS PLC
422,167$2.4B0.05%
106
KNSAKINIKSA PHARMACEUTICALS LTD
130,000$2.4B0.05%
107
1T7TRICIDA INC
427,975$2.3B0.05%
108
GRCLGRACELL BIOTECHNOLOGIES INC
125,000$1.9B0.04%
109
ORTXUSDORCHARD THERAPEUTICS PLC
256,649$1.9B0.04%
110
CRDFCARDIFF ONCOLOGY INC
150,000$1.4B0.03%
111
ARNAEURARENA PHARMACEUTICALS INC
20,000$1.4B0.03%
112
ASNSUSDX4 PHARMACEUTICALS INC
103,980$895.0M0.02%
113
FATEFATE THERAPEUTICS INC
10,000$824.0M0.02%
114
IMV1EURIMV INC
234,374$772.0M0.02%
115
NERVGBPMINERVA NEUROSCIENCES INC
200,000$584.0M0.01%
116
CEREVEL THERAPEUTICS HLDNG I
133,331$563.0M0.01%
117
OUTLOOK THERAPEUTICS INC
416,666$421.0M0.01%
118
NKTREURNEKTAR THERAPEUTICS
20,000$400.0M0.01%
119
NUVB/WSNUVATION BIO INC
83,332$222.0M0.00%
PreviousPage 2 of 2